1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Alpa Laboratories Limited

Alpa Laboratories Limited

ALPA.NS
Alpa Laboratories LimitedIN flagNational Stock Exchange of India
68.41
INR
-0.31
- -
1.44BMarket Cap
Alpa Laboratories Limited
ALPA.NS
(National Stock Exchange of India)

Recent

price

68.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
39.38
26.2
26.72
26.95
27.1
25.44
29.72
29.42
36.32
40.34
45.82
52.52
43.92
51.29
53.85
- -
49.37
Revenue per Share
0.43
0.25
-2.08
-2.45
-0.66
3.25
1.2
1.33
0.48
0.88
3.44
6.7
5.98
7.97
9.34
- -
7.08
Basic EPS, GAAP
1.92
-0.75
-0.63
2.79
-1.42
-15.41
7.4
-7.94
-0.88
7.24
-2.34
3.68
3.7
1.73
3.38
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
20.12
20.37
18.33
15.85
14.92
17.68
12.52
20.24
20.69
21.58
25.04
31.73
37.84
46.08
55.78
- -
9.82
Book Value per Share
46.24
46.5
44.5
41.97
40.87
39.93
42.14
44.44
45.85
47.7
51.13
57.81
63.92
72.17
82.08
- -
86.89
Tangible Book Value per Share
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
- -
21
Basic Weighted Avg Shares
829
551
561
567
574
536
625
619
764
849
964
1,105
924
1,079
1,125
1,058
1,058
Sales/Revenue/Turnover
0.76
2.84
-2.83
-5.97
-3.19
15.52
9.05
3.44
-0.6
5.33
10.08
8.63
7.95
7.22
2.27
1.13
1.13
Operating Margin (%)
11
10
47
91
61
8
28
31
31
32
12
17
13
20
22
21
21
Depreciation Expense
9
5
-44
-52
-14
68
25
28
10
19
72
141
126
168
195
150
152
Net Income, GAAP
16.45
36.76
- -
- -
- -
29.69
55.32
39.51
63.29
36.25
32.81
27.96
20.81
18.88
24.01
10.11
9.17
Effective Tax Rate (%)
1.09
0.96
-7.78
-9.09
-2.44
12.77
4.03
4.53
1.32
2.18
7.52
12.75
13.62
15.55
17.34
14.19
14.33
Profit Margin (%)
256
324
212
205
714
754
749
744
718
747
884
1,066
1,167
1,329
1,458
1,584
1,584
Working Capital
- -
27
62
42
- -
- -
5
6
4
2
- -
21
8
- -
- -
- -
- -
LT Debt
973
978
935
883
866
922
947
975
985
1,004
1,076
1,217
1,346
1,519
1,714
1,863
1,863
Total Equity
0.5
0.92
- -
- -
- -
5.05
2.28
1.23
-0.16
2.86
6.22
5.76
4.32
4.27
1.18
0.6
0.6
Return on Invested Capital (%)
1.79
1.01
- -
- -
- -
12.73
6.59
7.66
2.53
4.21
14.72
22.58
16.37
18.51
18
21.77
21.99
Return on Capital (%)
2.16
1.24
-10.74
-14.35
-4.3
19.89
7.93
8.14
2.35
4.17
14.78
23.59
17.19
19
18.28
21.83
22.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
25
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
- -
21
Market Capitalization
1,924
1,691
996

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,073
- -
2,109
Cash, Cash Equivalents & STI
1,401
- -
1,408
Accounts Receivable, Net
368
- -
408
Inventories
164
- -
133
Total Current Liabilities
498
- -
525
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
25
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.39%
11.61%
8.66%
Free Cash Flow
-167.22%
-35.16%
40.98%
Net Income, GAAP
36.87%
22.06%
-23.04%
Sales/Revenue/Turnover
7.71%
2.66%
-5.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
214
324
273
228
1,079
2025
214
249
262
399
1,125
2026
191
263
290
314
1,058

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.68
2.75
2.17
- -
7.97
2025
2.42
3.66
4.23
-0.95
9.34
2026
5.59
0.05
0.9
0.66
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
MGC Pharmaceuticals Limited (MGCLF)
Aurora Cannabis Inc. (ACB)
Parallel Industries Inc. (EAPH)
Pharma Foods International Co., Ltd. (2929.T)
Pharmaxis Ltd (PXS.AX)
Planet Based Foods Global Inc. (PBFFF)
Business
Alpa Laboratories Limited manufactures and sells pharmaceutical finished dosage forms in India. The company produces a wide range of ethical, generic, and over-the-counter (OTC) drugs for human and veterinary use, including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams, and gels; its product portfolio covers therapeutic categories such as anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics, anti-inflammatory drugs, cough and cold preparations, cardiovascular drugs, anti-diabetics, nutritional supplements, psychotropic drugs, skin care preparations, and ear and eye care products. Alpa Laboratories operates WHO-GMP and ISO 9001:2000 certified manufacturing facilities at Pigdamber, near Indore, Madhya Pradesh, spanning 1.20 acres with dedicated production areas designed for high output and quality; it sells products under its own brands through distributors, retail chemists, pharmacy stores, and hospitals, while also serving as a contract manufacturer for Indian and multinational companies. Founded in 1967 and headquartered in Indore, India, the company exports to South and Central America, Africa, Asia, Russia, Ukraine, Kazakhstan, and other international markets. In recent developments, Alpa Laboratories announced the acquisition of land at Pithampur for expansion; appointed Ms. Srashti Chopra as Company Secretary and Compliance Officer; changed the designation of Mr. Vitthal Kothana from Non-Executive to Executive Director; and reported consolidated financial results for quarters ended December 2024, September 2024, June 2025, and the full year ended March 31, 2025, alongside multiple disclosures under SEBI (SAST) Regulations for share acquisitions by promoters and related parties.